2,4-二氟扁桃酸 | 132741-30-1

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-二氟扁桃酸
• 中文别名: 2,4-二氟苯基乙醇酸
• 英文名称: 2-(2,4-difluorophenyl)-2-hydroxyacetic acid
• 英文别名: 2,4-difluoro-mandelic acid；2,4-difluoromandelic acid
• CAS: 132741-30-1
• 化学式: C₈H₆F₂O₃
• 分子量: 188.131
• InChiKey: RRRQFGNNRJHLNV-UHFFFAOYSA-N

物化性质

• 熔点：
  220-221°C
• 沸点：
  306.5±37.0 °C(Predicted)
• 密度：
  1.522
• 稳定性/保质期：
  如果遵照规格使用和储存，则不会分解，未有已知危险反应。请避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2918199090
• 危险类别：
  IRRITANT
• 安全说明：
  S26,S36

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2,4-Difluoromandelic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2,4-Difluoromandelic acid
Ingredient name:
CAS number: 132741-30-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H6F2O3
Molecular weight: 188.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,4-二氟扁桃酸 在 硫酸 、 三溴化磷 作用下， 以 氯仿 为溶剂， 反应 96.0h， 生成 methyl bromo(2,4-difluorophenyl)acetate
  参考文献：
  名称：

  新的4-芳基-1,3,2-氧杂噻唑-5-油酸酯：一系列新的S-亚硝基硫醇的化学合成和光化学稳定性

  摘要：

  S-亚硝基硫醇（RSNO）仍然是最流行的NO供体化合物之一，因为它们能够在非酶促方式下释放一氧化二氮（NO），同时产生惰性的二硫化物副产物。然而，由于这些化合物在包括热，光和铜离子存在在内的各种条件下固有的不稳定性，将这些化合物归入NO研究的不同生物学领域已被证明是有问题的。1,3,2-氧杂恶唑基-5-油酸酯（OZO）代表S的一个有趣子类-亚硝基硫醇将–SNO部分锁定在五元杂环中，以试图改善化合物的整体稳定性。全面研究了一系列新型的含卤素OZO的合成，得出了七步路线，总收率在21％到37％之间。评估了这些化合物的光化学稳定性，以确定与这些非环状对应物相比，锁定在这些中离子环系统内的S-亚硝基硫醇是否可以提供更高的稳定性，从而以更可控的方式释放NO。

  DOI：

  10.1016/j.bmcl.2018.01.059
• 作为产物：
  描述：

  2,4-二氟苯甲醛 在 盐酸 、 水 、 sodium hydrogensulfite 作用下， 以 1,4-二氧六环 、 乙醚 为溶剂， 反应 8.0h， 生成 2,4-二氟扁桃酸
  参考文献：
  名称：

  脂肪酶PS-30催化的立体选择性酰化反应对扁桃酸酯的动力学拆分

  摘要：

  通过使用脂肪酶PS-30作为催化剂，已通过立体选择性酰化反应实现了一系列外消旋扁桃酸酯的动力学拆分。动力学对映体比率（E）的值达到197.5。简要讨论了取代基的作用。

  DOI：

  10.1016/j.tetlet.2014.02.095

文献信息

• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。
• 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
  申请人：Neustadt R. Bernard

  公开号：US20070066620A1

  公开（公告）日：2007-03-22

  Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R 1 -isoxazolyl, R 1 -oxadiazolyl, R 1 -dihydrofuranyl, R 1 -pyrazolyl, R 1 -imidazolyl, R 1 -pyrazinyl or R 1 -pyrimidinyl; R 1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.

  具有结构式I或其药用可接受盐的化合物，其中R是R1-异噁唑基、R1-噁唑啉基、R1-二氢呋喃基、R1-吡唑基、R1-咪唑基、R1-吡啶基或R1-嘧啶基；R1是从H、烷基、烷氧基和卤代中选择的1、2或3个取代基；Z是可选择取代的芳基或可选择取代的杂芳基；公开了这些化合物及其在治疗中枢神经系统疾病，特别是帕金森病和额外锥体综合征中的用途，包括它们的药物组合物和与其他药剂的组合。
• COFERONS AND METHODS OF MAKING AND USING THEM
  申请人：Barany Francis

  公开号：US20120295874A1

  公开（公告）日：2012-11-22

  The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.

  本发明涉及一种用于制备治疗性化合物的单体。该单体包括一个或多个可与目标分子结合的药效团，其解离常数小于300微摩尔，以及与药效团连接的连接元素。所述连接元素的分子量小于500道尔顿，通过直接连接或通过连接器间接与药效团相连。
• One-pot, single-step deracemization of 2-hydroxyacids by tandem biocatalytic oxidation and reduction
  作者：Ya-Ping Xue、Yu-Guo Zheng、Ya-Qin Zhang、Jing-Lei Sun、Zhi-Qiang Liu、Yin-Chu Shen

  DOI：10.1039/c3cc46240d

  日期：——

  A facile and efficient one-pot, single-step method for deracemizing a broad range of 2-hydroxyacids to (R)-2-hydroxyacids was established by combination of resting cells of an (S)-hydroxyacid dehydrogenase-producing microorganism and an (R)-ketoacid reductase-producing microorganism.

  通过将产生（S）-羟酸脱氢酶的微生物的静止细胞与（ R）-产生酮酸还原酶的微生物。
• Highly Efficient Deracemization of Racemic 2-Hydroxy Acids in a Three-Enzyme Co-Expression System Using a Novel Ketoacid Reductase
  作者：Ya-Ping Xue、Chuang Wang、Di-Chen Wang、Zhi-Qiang Liu、Yu-Guo Zheng

  DOI：10.1007/s12010-018-2760-0

  日期：2018.11

  coli (HADH-LlKAR-GDH) co-expressing 2-hydroxyacid dehydrogenase, LlKAR, and glucose dehydrogenase was constructed for efficient deracemization of racemic 2-HAs. Most of the racemic 2-HAs were deracemized to their (R)-isomers at high yields and enantiomeric purity. In the case of racemic 2-chloromandelic acid, as much as 300 mM of substrate was completely transformed into the optically pure (R)-2-chloromandelic

  对映纯2-羟基酸（2-HAs）是合成药物和精细化学品的重要中间体。外消旋2-HA脱硫成相应的单个对映体代表了一种工业上合成手性2-HA的经济高效的方法。在这项工作中，通过基因组挖掘发现了一种来自乳酸乳球菌（LlKAR）的新的酮酸还原酶，该酶具有更高的活性和对芳香族α-酮酸的底物耐受性，然后对其酶学性质进行了表征。因此，构建了共表达2-羟酸脱氢酶，LlKAR和葡萄糖脱氢酶的工程化大肠杆菌（HADH-L1KAR-GDH），以有效地消旋外消旋2-HA。大部分外消旋2-HA均以高收率和对映体纯度脱硫为它们的（R）异构体。